Annals of Hematology

, Volume 90, Issue 10, pp 1225–1226 | Cite as

Long-term anticoagulation with fondaparinux in a patient with a mechanical heart valve

  • Michael Nagler
  • Michael Haslauer
  • Walter A. WuilleminEmail author
Letter to the Editor


Enoxaparin Fondaparinux Thromboembolic Complication Dalteparin Mechanical Heart Valve 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Financial support


Conflict of interest

Dr. Wuillemin reports receiving lecture honoraria and consulting fees from Bayer, GlaxoSmithKline, Pfizer and Sanofi-Aventis. Dr. Haslauer is an employee of GlaxoSmithKline. There is no other potential conflict of interest relevant to this article.


  1. 1.
    Bestmann L, Zuger M, Oldenburg J, Buhler D, Maly FE (2001) Coagulation factor IX propeptide mutations causing coumarin hypersensitivity: identification of female alanine-10 valine heterozygotes. Thromb Haemost 85(3):567–568PubMedGoogle Scholar
  2. 2.
    Donat F, Duret JP, Santoni A, Cariou R, Necciari J, Magnani H, de Greef R (2002) The pharmacokinetics of fondaparinux sodium in healthy volunteers. Clin Pharmacokinet 41(Suppl 2):1–9PubMedCrossRefGoogle Scholar
  3. 3.
    Mant T, Fournie P, Ollier C, Donat F, Necciari J (2002) Absence of interaction of fondaparinux sodium with digoxin in healthy volunteers. Clin Pharmacokinet 41(Suppl 2):39–45PubMedCrossRefGoogle Scholar
  4. 4.
    Ollier C, Faaij RA, Santoni A, Duvauchelle T, van Haard PM, Schoemaker RC, Cohen AF, de Greef R, Burggraaf J (2002) Absence of interaction of fondaparinux sodium with aspirin and piroxicam in healthy male volunteers. Clin Pharmacokinet 41(Suppl 2):31–37PubMedCrossRefGoogle Scholar
  5. 5.
    Decousus H, Prandoni P, Mismetti P, Bauersachs RM, Boda Z, Brenner B, Laporte S, Matyas L, Middeldorp S, Sokurenko G, Leizorovicz A (2010) Fondaparinux for the treatment of superficial-vein thrombosis in the legs. N Engl J Med 363(13):1222–1232PubMedCrossRefGoogle Scholar
  6. 6.
    Shetty R, Seddighzadeh A, Parasuraman S, Vallurupalli NG, Gerhard-Herman M, Goldhaber SZ (2007) Once-daily fondaparinux monotherapy without warfarin for long-term treatment of venous thromboembolism. Thromb Haemost 98(6):1384–1386PubMedGoogle Scholar
  7. 7.
    Schlitt A, Buerke M, Hauroeder B, Peetz D, Hundt F, Bickel C, Schaefer I, Meyer J, Rupprecht HJ (2003) Fondaparinux and enoxaparin in comparison to unfractionated heparin in preventing thrombus formation on mechanical heart valves in an ex vivo rabbit model. Thromb Haemost 90(2):245–251PubMedGoogle Scholar
  8. 8.
    Schlitt A, Hamilton K, Maegdefessel L, Dahm M, Theis C, Eichler M, Brockmann O, Steinseifer U, Hauroeder B, Hitzler WE, Rupprecht HJ (2006) Comparison of fondaparinux, low molecular-weight heparin and unfractionated heparin in preventing thrombus formation on mechanical heart valves: results of an in-vitro study. J Heart Valve Dis 15(6):809–814PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Michael Nagler
    • 1
  • Michael Haslauer
    • 2
  • Walter A. Wuillemin
    • 1
    • 3
    Email author
  1. 1.Division of Haematology and Central Haematology LaboratoryLuzerner KantonsspitalLucerne 16Switzerland
  2. 2.GlaxoSmithKline AGMünchenbuchseeSwitzerland
  3. 3.University of BerneBerneSwitzerland

Personalised recommendations